Cortica vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 53)
Cortica logo

Cortica

ChallengerHealthcare

Autism & Neurodevelopmental Care

Multispecialty pediatric provider integrating ABA, speech, OT, and medical care for autism and neurodevelopmental conditions. $80M raised Nov 2024; value-based care partnerships.

AI VisibilityBeta
Overall Score
C53
Category Rank
#229 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
55
Perplexity
53
Gemini
56

About

Cortica is a multispecialty pediatric healthcare organization delivering integrated care for children with autism and other neurodevelopmental disorders. Founded in 2017, the company combines applied behavior analysis (ABA), speech-language therapy, occupational therapy, physical therapy, music therapy, and medical services — including gene sequencing, metabolic testing, EEG, nutrition evaluation, and medication management — under one clinical model. This whole-child approach differentiates Cortica from single-discipline ABA providers and positions it closer to an academic health system model for autism. Cortica raised $80M in November 2024 and is entering value-based care arrangements with payors. The company operates centers across multiple U.S. states and is expanding its service model to include adolescents and adults, addressing a significant gap in the autism care continuum.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

53
Overall Score
93
#229
Category Rank
#1
85
AI Consensus
80
stable
Trend
stable
55
ChatGPT
94
53
Perplexity
89
56
Gemini
94
50
Claude
92
52
Grok
98

Key Details

Category
Autism & Neurodevelopmental Care
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.